keyword
MENU ▼
Read by QxMD icon Read
search

Alemtuzumab

keyword
https://www.readbyqxmd.com/read/29792124/hypersensitivity-to-alemtuzumab-a-safe-and-effective-desensitization-protocol-a-case-report
#1
Diego Gutiérrez-Fernández, Mónica Saldaña-Valderas, Raquel de la Varga-Martínez, Antonio Foncubierta-Fernández, María J Fernández-Anguita, Maria Del C Fernández-Valle, Fermín Medina-Varo
We describe a successful desensitization to alemtuzumab in one patient diagnosed with T-cell prolymphocytic leukaemia. Alemtuzumab treatment was initiated during infusion number 18, the patient showed cutaneous eruption with a miliary pattern, despite premedication with corticosteroids and antihistamines. The eruption returned with successive alemtuzumab infusions (infusions 19, 20 and 21), remained present for longer and was more severe with each infusion. The patient was referred to our Allergy Unit as it was necessary to maintain alemtuzumab treatment...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29744075/graves-orbitopathy-after-allogeneic-bone-marrow-transplantation-in-a-patient-with-fanconi-anemia-side-effect-of-alemtuzumab-therapy
#2
Luminita Nicoleta Cima, Ioana Maria Lambrescu, Lavinia Stejereanu, Anca Colita, Reuven Or, Simona Fica
A few cases of thyroid eye disease following alemtuzumab therapy have been described in patients with multiple sclerosis. Our patient is the first case of Graves' orbitopathy after alemtuzumab conditioning for hematopoietic stem cell transplantation.
May 2018: Clinical Case Reports
https://www.readbyqxmd.com/read/29731098/efficacy-and-safety-of-induction-therapy-in-kidney-transplantation-a-network-meta-analysis
#3
S D Hwang, J H Lee, S W Lee, K-M Park, J K Kim, M-J Kim, J H Song
BACKGROUND: Rejection and infection can occur after kidney transplantation and are important factors in preserving graft kidney function. The use of immunosuppressant agents in transplantation is therefore important, and the question of which induction therapy should be used as an immunosuppressant is controversial. OBJECTIVE: The goal of this study was to assess the comparative benefits and harms of various maintenance immunosuppressive induction agents in adults undergoing kidney transplantation by using a network meta-analysis and to generate rankings of the different immunosuppressive regimens according to their safety and efficacy...
May 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29730587/neutropenia-with-fatal-outcome-in-a-multiple-sclerosis-patient-23-days-after-alemtuzumab-infusion
#4
Konstantina G Yiannopoulou, Dimitra Papadimitriou, Aikaterini I Anastasiou, Marina Siakantaris
A 47-year-old Caucasian female with relapsing- remitting Multiple Sclerosis, received alemtuzumab after a serious relapse. She had ceased receiving any treatment during the previous year. 23 days after alemtuzumab infusion she developed severe early neutropenia, which resulted in septic shock by Staphylococcus aureus and death. This is the first report of alemtuzumab infusion-related death due to early neutropenia in non-immunocompromised MS patients. We suggest that the long existing safety guidelines for alemtuzumab infusion in B-cell chronic lymphocytic leukemia might be also beneficial in the MS setting...
April 28, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29722193/hypothalamic-demyelination-causing-panhypopituitarism
#5
Julia Dixon-Douglas, John Burgess, Michael Dreyer
Hypothalamic involvement in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) is rare and endocrinopathies involving the hypothalamic-pituitary axis in patients with demyelinating conditions have rarely been reported. We present two cases of MS/NMOSD with associated hypothalamic-pituitary involvement and subsequent hypopituitarism, including the first report of a patient with hypothalamic demyelination causing panhypopituitarism. Differential diagnoses, including alemtuzumab-related and primary pituitary pathology are discussed...
May 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29719098/allogeneic-hematopoietic-cell-transplant-following-crizotinib-monotherapy-for-relapsed-refractory-anaplastic-large-cell-lymphoma
#6
Tami D John, Swati Naik, Kathryn Leung, Ghadir Sasa, Caridad Martinez, Robert A Krance
Relapsed ALK-positive ALCL often is responsive to CRZ monotherapy. The subsequent role of allogeneic HCT after achieving second remission is poorly understood. We report 6 children who underwent allogeneic HCT for relapsed ALCL after CRZ. Age at transplant ranged from 10.7 to 22.6 years. Follow-up ranged from 0.9 to 4.5 years. All patients engrafted. Three of 4 patients that received a reduced-toxicity conditioning regimen containing fludarabine, alemtuzumab, and low-dose irradiation showed progressive mixed chimerism...
May 2, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29719014/mycosis-fungoides-clinical-and-histopathologic-features-differential-diagnosis-and-treatment
#7
Lorenzo Cerroni
Mycosis fungoides (MF) is the most common type of cutaneous lymphoma. The term MF should be used only for the classical presentation of the disease characterized by the evolution of patches, plaques, and tumors or for variants showing a similar clinical course. MF is divided into 3 clinical phases: patch, plaque, and tumor stage, and the clinical course is usually protracted over years or decades. Histopathologically, MF is characterized by an epidermotropic infiltrate of T lymphocytes that displays in most cases a helper phenotype...
March 2018: Seminars in Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29714032/alemtuzumab-versus-anti-thymocyte-globulin-in-patients-transplanted-from-an-unrelated-donor-after-a-reduced-intensity-conditioning
#8
Marie Robin, Kavita Raj, Sylvie Chevret, Jordan Gauthier, Hugues de Lavallade, David Michonneau, Donal McLornan, Régis Peffault de Latour, Victoria Potter, Austin Kulasekararaj, Flore Sicre de Fontbrune, Antonio Pagliuca, Ibrahim Yakoub-Agha, Gérard Socié, Ghulam J Mufti
OBJECTIVE: Relapse and graft-versus-host disease are still the main complications after allogeneic hematopoietic stem cell transplantation, especially in the setting of reduced intensity regimen (RIC) and unrelated donor. We compared here anti-thymocyte globulin (ATG) or alemtuzumab as GVHD prophylaxis in patients with myeloid disease transplanted after RIC and from an unrelated donor. METHOD: ATG- and alemtuzumab -patients have been matched by age, gender, HLA matching, comorbidities and cytogenetics risk (119 patients in each group)...
April 30, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29696498/alemtuzumab-as-rescue-therapy-in-a-cohort-of-50-relapsing-remitting-ms-patients-with-breakthrough-disease-on-fingolimod-a-multi-center-observational-study
#9
Konstantin Huhn, Antonios Bayas, Sebastian Doerck, Benedikt Frank, Kathrin Gerbershagen, Kerstin Hellwig, Boris Kallmann, Christoph Kleinschnitz, Ingo Kleiter, De-Hyung Lee, Volker Limmroth, Mathias Mäurer, Sven Meuth, Peter Rieckmann, Tobias Ruck, Ralf Gold, Ralf A Linker
BACKGROUND: Relapsing-remitting multiple sclerosis (RRMS) requires efficient immunomodulatory treatment to reach "no evidence of disease activity" status at best. Alemtuzumab and fingolimod have proved to be efficient options in RRMS with active disease course. Yet, side effects and break-through disease may limit long-time treatment and necessitate switch of medication. Data on efficacy and safety of alemtuzumab following fingolimod treatment are limited, but useful for clinical practice...
April 25, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29695598/preapproval-and-postapproval-evidence-on-drugs-for-multiple-sclerosis
#10
REVIEW
Chiara Gerardi, Vittorio Bertele', Silvia Rossi, Silvio Garattini, Rita Banzi
OBJECTIVE: To review the evidence supporting the European Union marketing authorization of drugs for multiple sclerosis (MS) and assess how far postmarketing research addresses information gaps at the time of approval. METHODS: Through its database, we identified drugs approved by the European Medicines Agency and gathered data on pivotal trials from the European Public Assessment Reports and corresponding publications. We searched Medline, Embase, Cochrane Library, and trial registries for postmarketing randomized controlled trials testing the drugs identified in any form of the disease...
April 25, 2018: Neurology
https://www.readbyqxmd.com/read/29686117/comprehensive-systematic-review-summary-disease-modifying-therapies-for-adults-with-multiple-sclerosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology
#11
Alexander Rae-Grant, Gregory S Day, Ruth Ann Marrie, Alejandro Rabinstein, Bruce A C Cree, Gary S Gronseth, Michael Haboubi, June Halper, Jonathan P Hosey, David E Jones, Robert Lisak, Daniel Pelletier, Sonja Potrebic, Cynthia Sitcov, Rick Sommers, Julie Stachowiak, Thomas S D Getchius, Shannon A Merillat, Tamara Pringsheim
OBJECTIVE: To review evidence on starting, switching, and stopping disease-modifying therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and progressive MS forms. METHODS: Relevant, peer-reviewed research articles, systematic reviews, and abstracts were identified (MEDLINE, CENTRAL, EMBASE searched from inception to November 2016). Studies were rated using the therapeutic classification scheme. Prior published Cochrane reviews were also used...
April 24, 2018: Neurology
https://www.readbyqxmd.com/read/29684788/pneumonitis-secondary-to-alemtuzumab-in-a-patient-with-multiple-sclerosis-a-non-infectious-cause-of-breathlessness
#12
D Whiteside, S Barth, A Datta, S A Trip
The most common adverse events associated with the monoclonal antibody alemtuzumab are infusion associated reactions and secondary autoimmune disease. Respiratory complications are unusual following treatment with alemtuzumab, but can be precipitated by an infectious cause. We describe a case of a sub-acute steroid responsive non-infectious pneumonitis affecting a 51 year old woman, who presented one month after initiation of therapy for multiple sclerosis with alemtuzumab.
April 3, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29679650/cmv-seronegative-donors-effect-on-clinical-severity-of-cmv-infection-and-reconstitution-of-cmv-specific-immunity
#13
P L J van der Heiden, H M van Egmond, S A J Veld, M van de Meent, M Eefting, L C de Wreede, C J M Halkes, J H F Falkenburg, W A F Marijt, I Jedema
BACKGROUND: Cytomegalovirus (CMV)-specific T-cells are crucial to prevent CMV disease. CMV seropositive recipients transplanted with stem cells from a CMV seronegative allogeneic donor (R+ D- ) may be at risk for CMV disease due to absence of donor CMV-specific memory T-cells in the graft. METHODS: We analyzed the duration of CMV reactivations and the incidence of CMV disease in R+ D- and R+ D+ patients after alemtuzumab-based T-cell depleted allogeneic stem cell transplantation (TCD alloSCT)...
April 18, 2018: Transplant Immunology
https://www.readbyqxmd.com/read/29666985/induction-of-disease-remission-with-one-cycle-of-alemtuzumab-in-relapsing-remitting-ms
#14
Alexandra S Kocsik, David E Klein, Maryana Liedke, Ulrike W Kaunzner, Nancy M Nealon, Susan A Gauthier, Timothy Vartanian, Jai S Perumal
OBJECTIVE: To investigate a single-course treatment with alemtuzumab in patients with relapsing-remitting multiple sclerosis. METHODS: We performed a retrospective chart review of all patients diagnosed with RRMS who were treated with alemtuzumab at our MS center and who had at least 12 month follow-up since the first dose. Data on radiological and clinical relapse were collected for the 2 years prior to patients' first dose of alemtuzumab and were tracked until the time of analysis...
April 17, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29663845/a-24-month-advanced-magnetic-resonance-imaging-study-of-multiple-sclerosis-patients-treated-with-alemtuzumab
#15
Irene M Vavasour, Roger Tam, David Kb Li, Cornelia Laule, Carolyn Taylor, Shannon H Kolind, Alex L MacKay, Adil Javed, Anthony Traboulsee
BACKGROUND: Tissue damage in both multiple sclerosis (MS) lesions and normal-appearing white matter (NAWM) are important contributors to disability and progression. Specific aspects of MS pathology can be measured using advanced imaging. Alemtuzumab is a humanised monoclonal antibody targeting CD52 developed for MS treatment. OBJECTIVE: To investigate changes over 2 years of advanced magnetic resonance (MR) metrics in lesions and NAWM of MS patients treated with alemtuzumab...
April 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29663814/new-biological-agents-in-the-treatment-of-multiple-sclerosis
#16
M Buc
Multiple sclerosis (MS) is an inflammatory disease induced by autoimmune processes. Their understanding has resulted in an introduction of biological agents to its treatment. Interferon beta and glatiramer acetate have been in clinical practice for more than 20 years. Nowadays, novel biologics, which target molecules involved in immunopathological processes more specifically have entered the scene. They are represented by monoclonal antibodies binding to molecules VLA4 (natalizumab), CD20 (ocrelizumab), CD52 (alemtuzumab) or alpha subunit of IL-2 receptor (daclizumab) or by small molecules such as those modulating the receptors involved in regulation of lymphocyte migration (fingolimod, ozanimod) or in induction of lymphopenia by apoptosis (dimethyl fumarate, cladribine)...
2018: Bratislavské Lekárske Listy
https://www.readbyqxmd.com/read/29661899/alemtuzumab-care-ms-i-5-year-follow-up-durable-efficacy-in-the-absence-of-continuous-ms-therapy
#17
(no author information available yet)
No abstract text is available yet for this article.
April 17, 2018: Neurology
https://www.readbyqxmd.com/read/29656137/haploidentical-peripheral-blood-stem-cell-transplantation-demonstrates-stable-engraftment-in-adults-with-sickle-cell-disease
#18
Santosh L Saraf, Annie L Oh, Pritesh R Patel, Karen Sweiss, Matthew Koshy, Sally Campbell-Lee, Michel Gowhari, Shivi Jain, David Peace, John G Quigley, Irum Khan, Robert E Molokie, Nadim Mahmud, Victor R Gordeuk, Damiano Rondelli
We report on the screening and development of haploidentical hematopoietic stem cell transplantation (HSCT) for adult patients with clinically aggressive sickle cell disease (SCD) at our institution. Of 50 adult SCD patients referred for HSCT between 1/2014-3/2017, 20% were denied by insurance. Of 41 patients initially screened, 10% lacked an available haploidentical donor, 29% had elevated donor specific antibodies (DSA) and 34% declined to proceed to HSCT. All 10 patients who were transplanted received peripheral blood stem cells (PBSC)...
April 12, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29620685/ebv-ptld-adenovirus-and-cmv-in-pediatric-allogeneic-transplants-with-alemtuzumab-as-part-of-pretransplant-conditioning-a-retrospective-single-center-study
#19
Margaret C Cupit-Link, Amulya Nageswara Rao, Deepti M Warad, Vilmarie Rodriguez, Shakila Khan
The risk of viral infections and reactivation occurring in the setting of pediatric allogeneic hematopoietic stem cell transplantation is a concern in the pediatric patient, especially with the use of Alemtuzumab (Campath) as a conditioning agent. The purpose of this study was to determine the incidence of Epstein-Barr virus posttransplant lymphoproliferative disorder (EBV-PTLD), cytomegalovirus (CMV), and adenovirus among pediatric recipients of alemtuzumab at our institution. We found that EBV-PTLD occurred in 2...
April 3, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29618462/allogeneic-hematopoietic-stem-cell-transplantation-for-severe-refractory-juvenile-idiopathic-arthritis
#20
Juliana M F Silva, Fani Ladomenou, Ben Carpenter, Sharat Chandra, Petr Sedlacek, Renata Formankova, Vicky Grandage, Mark Friswell, Andrew J Cant, Zohreh Nademi, Mary A Slatter, Andrew R Gennery, Sophie Hambleton, Terence J Flood, Giovanna Lucchini, Robert Chiesa, Kanchan Rao, Persis J Amrolia, Paul Brogan, Lucy R Wedderburn, Julie M Glanville, Rachael Hough, Rebecca Marsh, Mario Abinun, Paul Veys
Patients with juvenile idiopathic arthritis (JIA) can experience a severe disease course, with progressive destructive polyarthritis refractory to conventional therapy with disease-modifying antirheumatic drugs including biologics, as well as life-threatening complications including macrophage activation syndrome (MAS). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative immunomodulatory strategy for patients with such refractory disease. We treated 16 patients in 5 transplant centers between 2007 and 2016: 11 children with systemic JIA and 5 with rheumatoid factor-negative polyarticular JIA; all were either refractory to standard therapy, had developed secondary hemophagocytic lymphohistiocytosis/MAS poorly responsive to treatment, or had failed autologous HSCT...
April 10, 2018: Blood Advances
keyword
keyword
41276
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"